Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from Neumora Therapeutics, Inc. ( (NMRA) ).
Neumora Therapeutics, Inc. presented a corporate update at the J.P. Morgan Healthcare Conference, highlighting its efforts in neuroscience drug development. The company, backed by a strong financial position with $850 million raised since 2021, aims to capitalize on multiple clinical catalysts expected in 2025, targeting a significant patient population across various neuropsychiatric and neurodegenerative disorders.
More about Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc. operates in the biotechnology industry, specializing in the development of novel neuroscience drugs. The company’s focus is on creating therapies that improve treatment outcomes and quality of life for patients with brain diseases, leveraging a robust pipeline with intellectual property protections extending into the 2040s.
YTD Price Performance: 12.18%
Average Trading Volume: 2,632,078
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $357M
For an in-depth examination of NMRA stock, go to TipRanks’ Stock Analysis page.
